Results 81 to 90 of about 10,206 (212)
Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol [PDF]
, 2011 Peter T. Daley‐Yates, David A. Parkins
openalex +1 more source
Determination of the enantiomers of salmeterol xinafoate in salmeterol fluticasone powder inhalant by chiral nonaqueous capillary electrophoresis [PDF]
, 2021 Xu ZHANG +4 more
openalex +1 more source
Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer [PDF]
, 2010 Karine Clearie +5 more
openalex +1 more source
Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline
, 1998 S. Nutini, Tri Martini, Riccardo Righi
openalex +1 more source
Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs [PDF]
, 2002 David A. Stempel +2 more
openalex +1 more source
Педиатрическая фармакология, 2006 Open prospective randomized study in parallel groups was carried out to evaluate clinical (the amount of children who reached the control level by goal) and pathogenetic (the influence on the dynamics of the antiapoptotic eosinophil effectors expression)
L.M. Ogorodova, I.A. Deev, I.I. Ivanchuk
doaj
Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol [PDF]
, 2005 I. Peyron +3 more
openalex +1 more source
International Journal of COPD, 2011 Keisaku Fujimoto1, Yoshiaki Kitaguchi2, Shintaro Kanda2, Kazuhisa Urushihata2, Masayuki Hanaoka2, Keishi Kubo21Department of Biomedical Laboratory Sciences, 2First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano,
Fujimoto K +5 more
doaj